Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions
Generated by AI AgentAinvestweb
Monday, Aug 25, 2025 10:23 pm ET1min read
CARL--
Forward-Looking Analysis
Analysts expect CarlsmedCARL-- to report Q2 2025 earnings after market close on August 28, 2025, with the company hosting a conference call at 1:30 PM PT. Current projections indicate an estimated revenue of $11.5 million, up from Q1’s $10.19 million. While net income is expected to remain in the red, EPS is forecasted at -$0.24, showing slight improvement from Q1’s -$0.26. Analysts have not issued recent upgrades or downgrades, and no price targets were reported. The focus remains on the company’s AI-enabled personalized spine surgery solutions driving long-term growth.
Historical Performance Review
In Q1 2025, Carlsmed reported revenue of $10.19 million and a net loss of $5.73 million, or $0.26 per share. Gross profit stood at $7.64 million. The company continues to operate at a loss but has shown revenue growth compared to prior periods, indicating potential for improved efficiency and product adoption in the AI-enabled spine surgery segment.
Additional News
Carlsmed is set to report Q2 2025 results on August 28, 2025, after market close, with a conference call and webcast scheduled at 1:30 PM PT. No major non-earnings news was reported recently. The stock gained 1.24% on a recent update. The company maintains a market cap of $332.78 million and an enterprise value of $306.43 million. No significant M&A or product launch announcements were noted.
Summary & Outlook
Carlsmed continues to operate at a loss but shows steady revenue growth, driven by its AI-enabled spine surgery solutions. While net income and EPS remain negative, the company is on a path of improving efficiency and product adoption. The key growth catalyst is the expansion of personalized AI-driven solutions in the medical technology space. With a strong market cap and upcoming earnings release, Carlsmed remains in a cautiously optimistic position for long-term investors.
Analysts expect CarlsmedCARL-- to report Q2 2025 earnings after market close on August 28, 2025, with the company hosting a conference call at 1:30 PM PT. Current projections indicate an estimated revenue of $11.5 million, up from Q1’s $10.19 million. While net income is expected to remain in the red, EPS is forecasted at -$0.24, showing slight improvement from Q1’s -$0.26. Analysts have not issued recent upgrades or downgrades, and no price targets were reported. The focus remains on the company’s AI-enabled personalized spine surgery solutions driving long-term growth.
Historical Performance Review
In Q1 2025, Carlsmed reported revenue of $10.19 million and a net loss of $5.73 million, or $0.26 per share. Gross profit stood at $7.64 million. The company continues to operate at a loss but has shown revenue growth compared to prior periods, indicating potential for improved efficiency and product adoption in the AI-enabled spine surgery segment.
Additional News
Carlsmed is set to report Q2 2025 results on August 28, 2025, after market close, with a conference call and webcast scheduled at 1:30 PM PT. No major non-earnings news was reported recently. The stock gained 1.24% on a recent update. The company maintains a market cap of $332.78 million and an enterprise value of $306.43 million. No significant M&A or product launch announcements were noted.
Summary & Outlook
Carlsmed continues to operate at a loss but shows steady revenue growth, driven by its AI-enabled spine surgery solutions. While net income and EPS remain negative, the company is on a path of improving efficiency and product adoption. The key growth catalyst is the expansion of personalized AI-driven solutions in the medical technology space. With a strong market cap and upcoming earnings release, Carlsmed remains in a cautiously optimistic position for long-term investors.
This internal account is for our software. It'll answer users' questions about subscription products, aiming to boost adoption and retention.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet